Healthcare equities are widely viewed as classic defensive holdings that can cushion portfolios amid shifting market cycles, and three popular US-listed healthcare ETFs – Vanguard Health Care ETF（VHT）、iShares Global Healthcare ETF（IXJ）和 State Street SPDR S&P Biotech ETF（XBI） – cater to distinct investing goals ranging from broad domestic exposure to global healthcare and niche biotech bets.
While all track the healthcare sector, differences in expense costs, geographic focus, portfolio construction and risk profiles lead to starkly different long-term investment outcomes.
| Metric | VHT | IXJ | XBI |
| Fund Provider | Vanguard | iShares | SPDR |
| Expense Ratio | 0.09% | 0.40% | 0.35% |
| One-Year Total Return | 17.0% (as of May 29) | 12.4% (as of May 29) | 62.20% (as of May 18) |
| Trailing 12-month Dividend Yield | 1.72% | 1.46% | 0.33% |
| 5-Year Beta | 0.64 | 0.58 | 0.85 |
| Total AUM | $18.5B | $3.6B | $8.2B |
Beta gauges volatility against the S&P 500 based on five years of monthly performance. One-year figures reflect trailing 12-month total returns, while dividend yields use past 12-month distribution data.
Over a five-year investment horizon, $1,000 initial capital grew to $1,254 via VHT and $1,238 via IXJ, versus just $1,027 for XBI. The gap in downside protection is notable: VHT posted a five-year maximum drawdown of -17.7%, IXJ slid 18.1% at its worst, and XBI suffered a steep 54.7% peak-to-trough decline over the same stretch. The Vanguard vehicle also delivered far richer trailing 12-month per-share payouts of $4.70, compared with $1.36 for IXJ and $0.44 for XBI.
VHT zeroes in on the U.S. healthcare market with 411 individual stocks spanning large, mid and small-cap names across the full healthcare industry, allocating 100% of assets to the sector. Its top three holdings are Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV). Launched in 2004, the fund’s broad lineup lets investors tap smaller domestic healthcare firms often left out of more concentrated peer portfolios.
IXJ targets worldwide healthcare stocks with only 114 holdings and a 99% sector allocation plus minor cash reserves. Though its top-weighted names overlap with VHT’s core pharma giants, the global mandate opens investors to overseas healthcare businesses alongside extra risks from currency swings and divergent regional pharmaceutical regulations and pricing rules. The iShares product debuted back in 2001.
XBI is a niche play focused exclusively on biotech. With 151 securities under a modified equal-weight index methodology, it tilts heavily toward small and mid-sized emerging biotech operators rather than established pharmaceutical leaders, leading to far higher market volatility. Its top positions consist of smaller biotech players including Revolution Medicines (RVMD), Travere Therapeutics (TVTX) and Tg Therapeutics (TGTX).
Fund selection ultimately hinges on an investor’s geographic preference and risk appetite. Conservative investors building core defensive portfolio exposure tend to favor VHT thanks to its ultra-low expense ratio, steady dividend income and muted volatility. Those seeking global healthcare diversification can allocate modest capital to IXJ and accept its higher ongoing fees for cross-border market access. Aggressive traders hunting explosive biotech upside can set aside a small satellite position in XBI, mindful of its extreme downside risk.
Most balanced healthcare allocations center on VHT as the core holding, with optional tiny add-ons of IXJ for global diversification or XBI for speculative biotech upside.
